BioSpace News Archive

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

Data from Phase IIa show potent effect of Epeleuton on Triglyceride and HbA1C levels

Abacus Diagnostica is a small Finnish company developing and manufacturing assays and devices for rapid molecular diagnostics.

Havn Retail, a core pillar of Havn Life continues to reach milestones as the company works towards its launch of a line of retail products

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the opening of its new COVID-19 testing facility at Düsseldorf Airport.

Creavo Medical Technologies Ltd, the medical device company developing innovative diagnostics techniques, has announced that it has appointed Martin Frost as Chairman of the Board of Directors.

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057’s safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals.

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced the pricing of $500 million aggregate principal amount of 0.25% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Athenex, Inc. announced that the U.S. Food and Drug Administration has allowed its Investigational New Drug application for TCRT-ESO-A2, an autologous T cell receptor -T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients.

- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions - MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP